Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
Research and development	$ 4,880	$ 5,210	$ 20,430	$ 14,987
General and administrative	2,262	5,035	7,961	16,731
In process research and development	0	0	0	22,670
Total operating expenses	7,142	10,245	28,391	54,388
Loss from operations	(7,142)	(10,245)	(28,391)	(54,388)
Other expense (income), net	366	(360)	1,355	249
Net loss	$ (7,508)	$ (9,885)	$ (29,746)	$ (54,637)
Net loss per share, basic	$ (0.09)	$ (0.11)	$ (0.34)	$ (0.85)
Net loss per share, diluted	$ (0.09)	$ (0.11)	$ (0.34)	$ (0.85)
Weighted average number of shares of common stock used in computing net loss per share, basic	86,656,221	86,208,754	86,653,811	64,428,187
Weighted average number of shares of common stock used in computing net loss per share, diluted	86,656,221	86,208,754	86,653,811	64,428,187